What we do

We aim to repair tissues and regenerate organs using cell signaling technology

Our first target is the liver space. The liver is a critical organ of the body that is responsible for an array of functions. Any downfall of its functioning leads to failure of other vital organs and ultimately death.

With HepaStem®, Cellaïon aims to stop the progression of chronic liver disease, control inflammation, stop fibrous tissue accumulation in the liver and eventually allow organ recovery and regeneration of the liver.

Our lead product, HepaStem®, acts as a therapeutic cargo, delivering to the liver and inflamed tissues appropriate immunomodulatory signals with specific anti-inflammatory, anti-fibrotic and regenerative activities.

HepaStem® is being developed to cover a broad spectrum of liver diseases, from life-threatening acute-on-chronic liver failure (ACLF) and acute alcoholic hepatitis (AAH) to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH).

More than 100 patients have already received HepaStem®, which is easily administered by simple peripheral vein infusion. The very high safety profile of HepaStem® is supported by data accumulated over more than 10 years of follow-up.

Our proof-of-concept Phase IIb trial in ACLF is ongoing in many European countries and will be further extended into Latin America.



Acute-on-chronic liver failure (ACLF) is a well-recognized clinical entity affecting patients with chronic liver disease and characterized by a sudden deterioration of the liver followed by the failure of other vital organs, such as kidney, brain, lung or heart. ACLF has a mortality ranging from 42% to 75% at 3 months.

Play Video


Non-alcoholic Steatohepatitis

Progressive non-alcoholic steatohepatitis (NASH) is the most severe manifestation of non-alcoholic fatty liver disease (NAFLD). NASH is closely related to the triple epidemic of obesity, hyperlipidemia and type 2 diabetes. The chronic fat deposits can induce liver injury and sustained inflammation. NASH can progress to more serious disease stages, such as advanced fibrosis, cirrhosis or liver cancer.



Acute decompensation of cirrhosis (AD) is defined as an acute deterioration of the liver function in a patient with cirrhosis and is characterized by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome and/or variceal hemorrhage. Patients with AD can develop ACLF.


Acute Alcoholic hepatitis

Acute alcoholic hepatitis (AAH) is the inflammation of the liver caused by excessive consumption of alcohol. It is a syndrome characterized by rapid onset of jaundice, malaise, tender hepatomegaly, and systemic inflammatory response. AAH can be sudden and is highly fatal, with a mortality above 50% at one year.